ZAVESCA

Zavesca (miglustat) reduces the formation of a certain protein in the body in people with type 1 Gaucher disease.

Gaucher disease is a genetic condition in which the body lacks the enzyme needed to break down certain fatty materials (lipids). Lipids can build up in the body, causing symptoms such as easy bruising or bleeding, weakness, anemia, bone or joint pain, enlarged liver or spleen, or weakened bones that are easily fractured.

Zavesca is used to treat mild to moderate type 1 Gaucher disease by people who cannot receive enzyme replacement therapy.

Zavesca may improve the condition of the liver, spleen, bones, and blood cells in people with Type I Gaucher disease. However, it is not a cure for this condition.

Zavesca may also be used for purposes not listed in this medication guide.

Zavesca (Miglustat) Capsules suppliers in India. Allevaire India New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

The order for Zavesca (Miglustat) Capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.

Medicine Name: Zavesca Capsules
Generic Name: Miglustat
Approval Date: 7/31/2003
Company Name: Actelion Pharmaceuticals.